Equities

Arcturus Therapeutics Holdings Inc

ARCT:NMQ

Arcturus Therapeutics Holdings Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)19.58
  • Today's Change-0.79 / -3.88%
  • Shares traded534.73k
  • 1 Year change+2.19%
  • Beta2.6511
Data delayed at least 15 minutes, as of Nov 12 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Arcturus Therapeutics Holdings Inc. is a global messenger RNA medicines and vaccine company. The Company is focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. In addition to its messenger RNA (mRNA) platform, its lipid nanoparticle (LNP) delivery system, LUNAR, has the potential to enable multiple nucleic acid medicines, and its self-amplifying mRNA technology (Self-Transcribing and Replicating RNA (STARR), technology) has the potential to provide longer-lasting RNA and sustained protein expression at lower dose level. It is leveraging its LUNAR platform and its nucleic acid technologies to develop and advance a pipeline of mRNA-based vaccines and therapeutics for infectious diseases and rare genetic disorders with significant unmet medical needs. Its COVID-19 vaccine candidate, which is based on its STARR technology platform is through Phase II clinical trials.

  • Revenue in USD (TTM)160.40m
  • Net income in USD-62.64m
  • Incorporated2019
  • Employees180.00
  • Location
    Arcturus Therapeutics Holdings Inc10628 Science Center Dr Ste 250SAN DIEGO 92121-1132United StatesUSA
  • Phone+1 (858) 900-2660
  • Fax+1 (302) 636-5454
  • Websitehttps://arcturusrx.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Altimmune Inc409.00k-101.35m522.37m59.00--3.42--1,277.19-1.62-1.620.00642.150.0023--1.466,932.20-56.83-39.62-61.41-42.58-----24,778.97-1,811.89----0.00--726.47-47.15-4.41---45.92--
Prime Medicine Inc591.00k-217.44m526.94m234.00--2.68--891.60-2.16-2.160.00581.640.0022----2,525.64-80.45---88.55-------36,791.71------0.00-------39.52------
Chromadex Corp91.67m1.49m535.45m106.00370.3115.51230.205.840.01890.01891.210.45211.673.0523.51864,792.402.70-42.114.08-65.1461.4559.681.62-30.642.35--0.0004--15.9921.5070.15---36.66--
Kezar Life Sciences Inc7.00m-98.57m542.84m58.00--0.3599--77.55-13.55-13.550.96220.670.0316----120,689.70-44.47-32.54-47.84-34.09-----1,408.11-4,308.11----0.0634-------49.28--10.08--
Verve Therapeutics Inc24.40m-197.03m543.54m255.00--1.07--22.28-2.46-2.460.30336.010.0382--8.4595,670.59-30.87---32.86-------807.62------0.00--505.77---27.12------
OmniAB Inc21.71m-62.38m543.55m106.00--1.85--25.03-0.6204-0.62040.21592.490.0585--2.80204,849.10-16.80---17.72-------287.29------0.00---42.17---126.65------
Kalvista Pharmaceuticals Inc0.00-141.77m544.32m150.00--2.76-----3.54-3.540.004.010.00----0.00-78.65-40.63-87.52-43.67-------2,972.81----0.00-------36.31---16.34--
MeiraGTx Holdings PLC8.12m-93.14m548.01m387.00--5.74--67.47-1.49-1.490.12981.240.0282--0.473319,384.25-32.29-26.40-40.66-32.66-----1,146.81-420.70---22.760.4759---11.95--35.17--12.37--
Q32 Bio Inc0.00-49.66m548.25m42.00--29.86-----7.44-7.440.001.510.00----0.00-27.86-34.98-33.25-37.92-------971.76----0.4079---63.97-26.32-2,156.96---60.90--
Arcturus Therapeutics Holdings Inc160.40m-62.64m550.85m180.00--2.11--3.43-2.33-2.335.959.670.3873--4.69891,105.60-15.13-19.66-18.67-24.90-----39.05-77.55----0.00---19.0360.31-417.95--14.44--
Aura Biosciences Inc0.00-80.69m552.61m88.00--2.89-----1.79-1.790.003.860.00----0.00-39.26---41.21--------------0.00-------30.03------
Sangamo Therapeutics Inc12.28m-249.68m562.20m405.00--23.73--45.79-1.38-1.380.06640.11380.0587--7.4530,313.58-119.44-26.09-153.51-31.04-----2,033.68-136.53----0.00--58.3415.85-34.09---13.25--
Regenxbio Inc84.33m-238.81m572.74m344.00--1.90--6.79-5.03-5.031.766.090.1463--3.27245,136.60-41.43-16.75-51.75-19.0854.3678.27-283.19-72.06----0.00---19.94-16.216.00---5.59--
Celcuity Inc0.00-82.59m581.37m55.00--3.29-----2.74-2.740.004.770.00----0.00-37.03-37.32-39.38-39.16------------0.3525-------57.99---31.12--
Data as of Nov 12 2024. Currency figures normalised to Arcturus Therapeutics Holdings Inc's reporting currency: US Dollar USD

Institutional shareholders

62.13%Per cent of shares held by top holders
HolderShares% Held
Federated Global Investment Management Corp.as of 30 Jun 20244.69m17.36%
Nikko Asset Management Americas, Inc.as of 30 Sep 20242.32m8.56%
ARK Investment Management LLCas of 30 Sep 20242.10m7.77%
BlackRock Fund Advisorsas of 30 Jun 20242.02m7.49%
SSgA Funds Management, Inc.as of 30 Jun 20241.52m5.64%
The Vanguard Group, Inc.as of 30 Jun 20241.32m4.90%
Morgan Stanley & Co. LLCas of 30 Jun 2024768.29k2.84%
Woodline Partners LPas of 30 Jun 2024754.02k2.79%
Dimensional Fund Advisors LPas of 30 Sep 2024741.36k2.74%
Fidelity Management & Research Co. LLCas of 30 Jun 2024555.50k2.05%
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.